References
- Maclean J, Rybicki EP, Williamson AL. Vaccination strategies for the prevention of cervical cancer. Expert Rev. Anticancer Ther.5, 97–107 (2005).
- Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine25, 3001–3006 (2007).
- Kjaer SK, Tran TN, Sparen P et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J. Infect. Dis.196, 1447–1454 (2007).
- Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann. Oncol.18, 1708–1715 (2007).
- Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol. Oncol.107(Suppl.), S2–S5 (2007).
- Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
- Carter JJ, Madeleine MM, Shera K et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res.61, 1934–1940 (2001).
- D’Souza G, Kreimer AR, Viscidi R et al. Case–control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med.356, 1944–1956 (2007).
- Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356, 1928–1943 (2007).
- FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356, 1915–1927 (2007).
- Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95, 1459–1466 (2006).
- Perez G, Lazcano-Ponce E, Hernandez-Avila M et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int. J. Cancer.122, 1311–1318 (2008).
- Hillemanns P, Breugelmans JG, Gieseking F et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect. Dis.8, 76 (2008).
- Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost–effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int. J. Technol. Assess. Health Care24(1), 10–19 (2008).
- Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S. Cost–effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr. Med. Res. Opin.24(5), 1473–1483 (2008).
- Kulasingam S, Connelly L, Conway E et al. A cost–effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health4(3), 165–175 (2007).
Websites
- Gardasil®: European Public Assessment Report www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm
- Ceravix®: European Public Assessment Report www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm